insights_auto
Bakit bumaba ang TRVN 99.24%?
Tingnan ang Higit pang Detalyechevron_right
TRVN:OTCMKTS
Trevena Inc
$0.00050
arrow_downward
-99.24%(-0.066) 1D
Okt 16, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa TRVN...
Buksan
$0.00
Mataas
$0.00
Mababa
$0.00
Mkt. cap
407.21
Avg. na dami
210.00
Dami
4.13K
Mataas nang 52-wk
$1.50
Mababa nang 52-wk
$0.00
Beta
1.07
Mga natitirang share
864.00K
Bilang ng mga empleyado
23
Buksan
$0.00
Mataas
$0.00
Mababa
$0.00
Mkt. cap
407.21
Avg. na dami
210.00
Dami
4.13K
Mataas nang 52-wk
$1.50
Mababa nang 52-wk
$0.00
Beta
1.07
Mga natitirang share
864.00K
Bilang ng mga empleyado
23
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
investingLive
·
13 oras ang nakalipas
S&P 500 analysis and forecast after the "AI bubble" panic
Bloomberg.com
·
1 araw ang nakalipas
S&P 500 Steady as Warsh Boosts Expectations of Rate Hold
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
24/7 Wall St.
·
5 araw ang nakalipas
You Bought VOO to Own the S&P 500. On $500,000, One Chipmaker Is $40,400 of It
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Tungkol sa Trevena Inc
CEO-
Mga Empleyado23
Itinatag2007
HeadquartersAtlanta, Georgia, Estados Unidos
Sektor-
Websitetrevena.com